1. Clinical & Scientific Overview
Docetaxel (TIP-MED-000562, Reference Code [ONC-13]) is classified under
Oncology & Antineoplastic Medicines as a Antimitotic Taxane (M-Phase Specific) • Semisynthetic Taxane Microtubule Stabiliser.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Taxotere (Sanofi India), Docetere (Dr. Reddy's Laboratories), Docecad (Cadila Pharmaceuticals)
Concentrate for IV Infusion: 20 mg, 80 mg, 120 mg vials (in Polysorbate 80 / ethanol vehicle)
Oncology Specialisation & Cytotoxic Safety Protocol
Antimitotic Taxane (M-Phase Specific)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: 75–100 mg/m2 IV over 1 hour every 21 days.
Signature Dose-Limiting Toxicities & Organ Monitoring: Severe Neutropenia (nadir Day 7–8), Cumulative Fluid Retention Syndrome (peripheral oedema, pleural effusion, and ascites due to capillary protein hyperpermeability), Polysorbate-80 acute hypersensitivity reactions, nail onycholysis, and sensory neuropathy.
Extravasation, Premedication & Safe Cytotoxic Handling: MANDATORY 3-DAY DEXAMETHASONE PREMEDICATION: Oral Dexamethasone 8 mg twice daily for 3 days starting 1 day BEFORE Docetaxel infusion (reduces fluid retention and anaphylaxis); CONTRAINDICATED if total bilirubin >ULN or AST/ALT >1.5x ULN with ALP >2.5x ULN (hepatic clearance slowdown causes fatal febrile neutropenia).
3. Mechanism of Action & Pharmacodynamics
Binds with high affinity to the beta-tubulin subunit of assembled microtubules, promoting polymerisation and preventing depolymerisation, which arrests mitotic spindle dynamics at the G2/M boundary.
4. Therapeutic Indications & Evidence-Supported Uses
- Early and metastatic Breast Cancer
- Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer
- Gastric Adenocarcinoma (FLOT) and NSCLC
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 75–100 mg/m2 IV over 1 hour every 21 days.
Administration & Meal Timing: 75–100 mg/m2 IV over 1 hour every 21 days.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Docetaxel or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Severe Neutropenia (nadir Day 7–8), Cumulative Fluid Retention Syndrome (peripheral oedema, pleural effusion, and ascites due to capillary protein hyperpermeability), Polysorbate-80 acute hypersensitivity reactions, nail onycholysis, and sensory neuropathy.
8. Adverse Effects Profile
- Severe Neutropenia (nadir Day 7–8), Cumulative Fluid Retention Syndrome (peripheral oedema, pleural effusion, and ascites due to capillary protein hyperpermeability), Polysorbate-80 acute hypersensitivity reactions, nail onycholysis, and sensory neuropathy.
- Severe Neutropenia (nadir Day 7–8), Cumulative Fluid Retention Syndrome (peripheral oedema, pleural effusion, and ascites due to capillary protein hyperpermeability), Polysorbate-80 acute hypersensitivity reactions, nail onycholysis, and sensory neuropathy.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Severe Neutropenia (nadir Day 7–8), Cumulative Fluid Retention Syndrome (peripheral oedema, pleural effusion, and ascites due to capillary protein hyperpermeability), Polysorbate-80 acute hypersensitivity reactions, nail onycholysis, and sensory neuropathy.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: MANDATORY 3-DAY DEXAMETHASONE PREMEDICATION: Oral Dexamethasone 8 mg twice daily for 3 days starting 1 day BEFORE Docetaxel infusion (reduces fluid retention and anaphylaxis); CONTRAINDICATED if total bilirubin >ULN or AST/ALT >1.5x ULN with ALP >2.5x ULN (hepatic clearance slowdown causes fatal febrile neutropenia).
Pharmacist Patient Counselling Points:
- MANDATORY 3-DAY DEXAMETHASONE PREMEDICATION: Oral Dexamethasone 8 mg twice daily for 3 days starting 1 day BEFORE Docetaxel infusion (reduces fluid retention and anaphylaxis); CONTRAINDICATED if total bilirubin >ULN or AST/ALT >1.5x ULN with ALP >2.5x ULN (hepatic clearance slowdown causes fatal febrile neutropenia).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: MANDATORY 3-DAY DEXAMETHASONE PREMEDICATION: Oral Dexamethasone 8 mg twice daily for 3 days starting 1 day BEFORE Docetaxel infusion (reduces fluid retention and anaphylaxis); CONTRAINDICATED if total bilirubin >ULN or AST/ALT >1.5x ULN with ALP >2.5x ULN (hepatic clearance slowdown causes fatal febrile neutropenia).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.